Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers Criticize: Psychotropic Drugs Are No Solution

By Ruhr-Universitaet-Bochum | September 16, 2016

Drugs don’t lead to sustainable alleviation of mental disorders, claim the psychologists Dr. Jürgen Margraf and Dr. Silvia Schneider in a commentary published in EMBO Molecular Medicine.

The researchers from Ruhr-Universität Bochum have compiled numerous studies that question the long-term effectiveness of psychotropic drugs; some even document negative effects after prolonged application. Psychotherapies, on the other hand, are effective in the long-term. The authors postulate that it is necessary to interlink the research into the biological, psychological and social factors, rather than reduce mental diseases to biological causes alone.

The currently available drugs cannot permanently alleviate the symptoms of mental disorders. This is the conclusion drawn by psychologists Margraf and Schneider

Effect of Drugs Are Only Short-Lived

Margraf and Schneider have compiled ample evidence suggesting that anti-depressant, anti-anxiety, and anti-ADHD drugs have only a short-term effect. If patients discontinue treatment, their symptoms return. The authors suspect that medication for the treatment of schizophrenia would yield similar results.

Long-term application of the drugs might even have a negative effect—for example, increased risk of a chronic illness or higher relapse quota.

Psychotherapies Are Not Available for Many Patients

According to the authors, psychotherapies such as cognitive behavioral therapy yield much better and more sustainable results in the long-term.

“The main problem with psychotherapy is not its effectiveness or costs,” says Schneider. “Rather, it is its insufficient availability.”

While psychotropic drugs can be applied straight away, patients often have to wait a long time for their first appointment with a therapist.

Biological Concepts Are Insufficient

In their article, the psychologists from Bochum also discuss the question why better therapies are still non-existent, despite 60 years of dedicated research. According to their opinion, one reason might be the ill-advised notion that mental disorders can be explained by biological concepts alone.

“Today, it has become standard to tell the patients and the public that mental disorders are caused by an imbalance in the neurotransmitter system,” said Margraf.

However, it is not yet clear if that phenomenon is the cause or the effect of the diseases. Social factors should not be neglected. According to Schneider and Margraf, the rigid categories of “ill” and “healthy” are not helpful at all with regard to mental disorders, which manifest in many different forms.

Fewer Psychotropic Drugs, More Psychotherapy

The authors postulate that it is necessary to link research into the biological, psychological, and social factors and to broaden the narrow view of possible biological causes. Large pharmaceutical companies should reduce the marketing of psychotropic drugs. Moreover, patients should be given access to psychotherapeutic services more quickly.

Reference

  1. Jürgen Margraf, Silvia Schneider. “From neuroleptics to neuroscience and from Pavlov to psychotherapy: more than just the ‘emperor’s new treatments’ for mental illnesses?” EMBO Molecular Medicine. 2016. e201606650. DOI: 10.15252/emmm.201606650.

To read the full press release, click here.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE